Literature DB >> 12748972

Construct validity of newly developed quality of life assessment instrument for child and adolescent cancer patients in Taiwan.

Chao-Hsing Yeh1, Li-Chen Hung.   

Abstract

The purpose of this study was to test the convergent, discriminant, and clinical validity of the Quality of Life in Childhood Cancer (QOLCC) instrument for measuring the quality of life of Taiwanese children who suffer from cancer. In total, 160 patients were recruited for the study, including 105 male and 55 female. Overall, QOLCC consisted of generic measure and disease-specific domains to assess the Quality of Life (QOL) for children treated for cancer. The QOLCC is a symptom or problem-based questionnaire with the conceptual framework that health-related problems can be solved from both a biomedical perspective (e.g. changing the patient's medical treatment can enhance the QOL) and from a biobehavioral perspective (e.g. problem solving on a daily basis). This QOLCC, which can be administered in 15 min, is the first documented measure of the QOL administered directly to Taiwanese Children. It demonstrates acceptable psychometric properties. Application of the QOLCC to Taiwanese children with cancer produced encouraging results, validation from a larger independent parent population is still necessary. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2003        PMID: 12748972     DOI: 10.1002/pon.647

Source DB:  PubMed          Journal:  Psychooncology        ISSN: 1057-9249            Impact factor:   3.894


  8 in total

1.  Psychometric evaluation of the Taiwanese version of the Kiddo-kINDL generic children's health-related quality of life instrument.

Authors:  Pi-Hsia Lee; Lu-I Chang; Ulrike Ravens-Sieberer
Journal:  Qual Life Res       Date:  2008-05       Impact factor: 4.147

Review 2.  Identifying determinants of quality of life of children with cancer and childhood cancer survivors: a systematic review.

Authors:  Anne F Klassen; Samantha J Anthony; Aalia Khan; Lillian Sung; Robert Klaassen
Journal:  Support Care Cancer       Date:  2011-05-25       Impact factor: 3.603

3.  Validation of pediatric Functional Assessment of Cancer Therapy: patient version 2 of "brain tumor survivor" for grade school patients aged 7-12 years.

Authors:  Heejung Yoo; Young-Shin Ra; Hyeon-Jin Park; Jin-Shei Lai; David Cella; Hee-Young Shin; Dong-Seok Kim; Woo-Chul Kim; Yong-Soon Shin
Journal:  Qual Life Res       Date:  2010-12-03       Impact factor: 4.147

Review 4.  Considering quality of life for children with cancer: a systematic review of patient-reported outcome measures and the development of a conceptual model.

Authors:  Samantha J Anthony; Enid Selkirk; Lillian Sung; Robert J Klaassen; David Dix; Katrin Scheinemann; Anne F Klassen
Journal:  Qual Life Res       Date:  2013-08-02       Impact factor: 4.147

5.  Starting from scratch: the development of the Adolescent Quality of Life-Mental Health Scale (AQOL-MHS).

Authors:  Ligia Chavez; Karen Mir; Glorisa Canino
Journal:  Cult Med Psychiatry       Date:  2012-09

Review 6.  Quality of life questionnaires for children with cancer and childhood cancer survivors: a review of the development of available measures.

Authors:  Anne F Klassen; Sonya J Strohm; Heleen Maurice-Stam; Martha A Grootenhuis
Journal:  Support Care Cancer       Date:  2009-10-16       Impact factor: 3.603

7.  Factor structure of the Singapore English version of the KINDL children quality of life questionnaire.

Authors:  Hwee-Lin Wee; Ulrike Ravens-Sieberer; Michael Erhart; Shu-Chuen Li
Journal:  Health Qual Life Outcomes       Date:  2007-01-19       Impact factor: 3.186

8.  Cross-cultural adaptation of the korean version of the minneapolis-manchester quality of life instrument-adolescent form.

Authors:  Hyeon Jin Park; Hyung Kook Yang; Dong Wook Shin; Yoon Yi Kim; Young Ae Kim; Young Ho Yun; Byung Ho Nam; Smita Bhatia; Byung Kiu Park; Thad T Ghim; Hyoung Jin Kang; Kyung Duk Park; Hee Young Shin; Hyo Seop Ahn
Journal:  J Korean Med Sci       Date:  2013-11-26       Impact factor: 2.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.